


WYTH0144-100
Serial No. 09/769,107



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Vincent P. Sandanayaka et al. **Confirmation No.:** 4495

Serial No.: 09/769,107

Art Unit No.: 1625

Filing Date: January 24, 2001

Examiner: Raymond K. Covington

For: **METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES**

Customer No.: 35139

Mail Stop:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EXPRESS MAIL LABEL NO: EV 513 563 587 US
DATE SENT: January 23, 2006

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08b, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- before the mailing date of a first Office Action on the merits.
- after the mailing date of a first Office Action on the merits or after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

09769107

01/26/2006 REFERRED 00000054 501275
02 FC:1806 180.00 DA

WYTH0144-100
Serial No. 09/769,107

or

the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or

No fee is owed by the applicant(s).

In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.

after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).

A copy of each reference listed on the attached PTO Form SB/08b, formerly known as PTO Form 1449 is enclosed herewith,

EXCEPT THAT:

In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.

In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Pursuant to Fed. Reg. Vol. 69, No. 182, dated September 21, 2004, copies of U.S. Patents and U.S. Patent Publications need not be submitted as part of an Information Disclosure Statement.

Statement under 37 C.F.R. § 1.97(e)

The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a

WYTH0144-100
Serial No. 09/769,107

foreign patent office in a counterpart application and the communication was not received by any individual designated in § 1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.


Fees

- No Fee is owed by the applicant(s).
- The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is authorized to be charged to Deposit Account No. 50-1275.

Method of Payment of Fees

- Attached is a check in the amount of \$_____ This form is submitted in duplicate.
- Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Michael A. Patané
Registration No. 42,982

Dated: January 23, 2006

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-6966 – Telephone
(215) 701-2080 - Facsimile



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1 of 2

Complete if Known	
Application Number	09/769,107
Filing Date	January 24, 2001
First Named Inventor	Sadanayaka
Art Unit	1625
Examiner Name	Covington
Attorney Docket Number	wyth0144-100 (AM100182-D1)

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Shire, M. G.; Muller, G. W. Exp. Opin. Ther. Patents 1998, 8(5), 531;	
		Grossman, J. M.; Brahn, E. J. Women's Health 1997, 6(6), 627;	
		Isomaki, P.; Punnonen, J. Ann. Med. 1997, 29, 499;	
		Camussi, G.; Lupia, E. Drugs, 1998, 55(5), 613]	
		Mathison, et. al. J. Clin. Invest. 1988, 81, 1925;	
		Miethke, et. al. J. Exp. Med. 1992, 175, 91],	
		Piguet, P. F.; Grau, G. E.; et al. J. Exp. Med. 1987, 166, 1280],	
		Beutler, B.; Cerami, A. Ann. Rev. Biochem. 1988, 57, 505],	
		Ksontini, R.; MacKay, S. L. D.; Moldawer, L. L. Arch. Surg. 1998, 133, 558	
		Packer, M. Circulation, 1995, 92(6), 1379;	
		Ferrari, R.; Bachetti, T.; et. al. Circulation, 1995, 92(6), 1479],	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	09/769,107
Filing Date	January 24, 2001
First Named Inventor	Sadanayaka
Art Unit	1625
Examiner Name	Covington
Attorney Docket Number	wyth0144-100 (AM100182-D1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hotamisligil, G. S.; Shargill, N. S.; Spiegelman, B. M.; et. al. Science, 1993, 259, 87	
		Peterson, P. K.; Gekker, G.; et. al. J. Clin. Invest. 1992, 89, 574;	
		Pallares-Trujillo, J.; Lopez-Soriano, F. J. Argiles, J. M. Med. Res. Reviews, 1995, 15 (6), 533],	
		Old, L. Science, 1985, 230, 630	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.